Southern Plains Medical Center of Garvin County LLC
Southern Plains Medical Center of Garvin County LLC was paid $1.29M by Medicaid between Sep 2021 and Dec 2024, across 46 billing codes. Its largest line is 99283, emergency room visit (moderate) — 30% of everything it billed.
33Billing provider infoSOUTHERN PLAINS MEDICAL CENTER OF GARVIN COUNTY LLC
PAULS VALLEY, OK 73075
PAULS VALLEY, OK 73075
33aNPI1053997338assigned 03/18/2021
33bProvider typeWound Care Registered Nurse
28Total paid$1.29M
24GClaims14,106
24DCodes billed46
24AFirst – last monthSep 2021 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 491 | $78K | |
| 2022 | 3,296 | $316K | |
| 2023 | 6,336 | $549K | |
| 2024incomplete | 3,983 | $349K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 30% | 2,183 | 2,155 | $386K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 29% | 1,421 | 1,373 | $379K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 8.5% | 1,559 | 1,438 | $110K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.3% | 281 | 275 | $94K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.9% | 708 | 699 | $77K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.5% | 413 | 398 | $59K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.8% | 334 | 333 | $24K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 1.8% | 336 | 312 | $23K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 317 | 303 | $18K |
| 80053 | Comprehensive metabolic panel | 1.3% | 724 | 693 | $16K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 808 | 564 | $12K |
| 36415 | Collection of venous blood by venipuncture | <1% | 852 | 827 | $11K |
34 more codes
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 322 | $9K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 165 | $8K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 322 | $8K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 148 | $7K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 135 | $7K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 39 | $5K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 779 | $5K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 60 | $5K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 221 | $5K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 260 | $4K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 102 | $4K |
| 71045 | Radiologic examination, chest; single view | <1% | 263 | $4K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 18 | $2K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 68 | $2K |
| 87481 | <1% | 47 | $1K | |
| 87641 | <1% | 40 | $1K | |
| 87500 | <1% | 40 | $1K | |
| 83874 | <1% | 54 | $685.06 | |
| 84484 | <1% | 54 | $661.21 | |
| 87420 | <1% | 53 | $646.61 | |
| 82553 | <1% | 54 | $612.33 | |
| 84512 | <1% | 54 | $525.86 | |
| 83605 | <1% | 51 | $514.50 | |
| 83735 | <1% | 87 | $494.51 | |
| 81003 | <1% | 191 | $344.77 | |
| 84100 | <1% | 81 | $331.47 | |
| 82550 | <1% | 53 | $329.63 | |
| 86403 | <1% | 12 | $112.86 | |
| 81025 | <1% | 14 | $107.24 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 16 | $87.04 |
| 94761 | <1% | 114 | $15.05 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 34 | $3.15 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 194 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHARMA, MADHUKAR (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Om Diagnostic Laboratories INC. | Norwood, MA | $1.05M |
| Ace Biomedical Labs, LLC | Jacksonville, FL | $222K |
| Forensic Stat Laboratory INC | Coral Springs, FL | $63K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.